Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (NYSE: BDX) celebrated 65 years of manufacturing at its Broken Bow, Nebraska facility on Oct. 16, 2025. The site opened Oct. 18, 1960 and has grown from a 13,753-square-foot plant with 20 associates to a 310,000-square-foot facility employing nearly 600 associates.
Broken Bow is described as the world's largest manufacturer of BD Vacutainer® tubes, producing billions of tubes and other collection products annually. BD reports more than $50 million invested in Nebraska since 2020 and announced a separate >$35 million investment and 50 jobs at its Columbus facility. BD operates 30+ U.S. sites with ~10,000 employees.
BD (NYSE: BDX) announced a CFO transition: Chris DelOrefice will depart effective Dec. 5, 2025 and Vitor Roque will become interim CFO. The company provided preliminary unaudited results for the period ended Sept. 30, 2025, including Q4 revenue ≈ $5.9 billion (reported +8.3%, currency‑neutral +7.0%, organic +3.9%) and full‑year revenue ≈ $21.8 billion (reported +8.2%, currency‑neutral +7.7%, organic +2.9%).
BD expects fiscal 2025 adjusted diluted EPS to be at or above the midpoint of prior guidance, and will discuss results on an audio webcast Nov. 6, 2025. Preliminary figures are unaudited and subject to change.
BD (NYSE: BDX) said management will host an audio webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to discuss fourth-quarter and full-year fiscal 2025 results (fiscal year ended September 30, 2025) and provide an operations and strategy update.
The company will issue a news release and presentation materials with summary financial information prior to the call. The live webcast and a replay will be available at www.bd.com/investors.
BD (NYSE: BDX) announced enrollment of the first patient in the XTRACT™ Registry on September 29, 2025, a prospective, multi-center, single-arm post-market study to evaluate real-world performance of the Rotarex™ Catheter System for peripheral artery disease (PAD).
The registry plans up to 600 patients across as many as 100 U.S. sites with follow-ups at 30 days, 6 months, and 12 months to assess safety and effectiveness. The Rotarex catheter offers combined atherectomy and thrombectomy mechanisms to remove plaque and thrombus. BD said the registry will generate real-world evidence to inform clinical decision-making and treatment strategies for PAD.
BD (NYSE: BDX) and Opentrons announced a multi-year collaboration on Oct 8, 2025 to integrate Opentrons robotic liquid-handling into BD single-cell multiomics instruments.
The partnership intends to integrate the BD Rhapsody System with the Opentrons Flex platform, develop verified protocols, and build an automation-compatible module to automate next-generation sequencing library preparation and cell capture, enabling hands-free workflows and scaling to million-cell studies.
Early access opportunities will be available and both companies will present details at the ASHG Annual Meeting, Oct 14–18, 2025 (BD Booth 447; Opentrons Booth 635).
BD (NYSE: BDX) celebrates 55 years of manufacturing at its Sumter, South Carolina facility on Oct. 3, 2025. The site began in 1970 with 25 employees and now spans >600,000 square feet, employs ~900 associates and produces billions of products annually, including BD Vacutainer® blood collection products that the company says care for 84 patients every second.
Since FY21, BD invested more than $90 million in Sumter, tripled year-over-year investment from FY24 to FY25, and plans to invest ~$30 million in FY26 for modernization, new lines and training. BD announced a $10,000 donation to the Tuomey Foundation and contributes >$100,000 annually to local organizations. BD operates >30 U.S. manufacturing and distribution sites across 17 states and Puerto Rico, employing >10,000 people.
BD (NYSE: BDX) has announced a groundbreaking pharmacy automation partnership with Henry Ford Health to revolutionize medication storage and prescription delivery. The collaboration centers on implementing the BD Rowa™ Vmax, a sophisticated pharmacy automation robot, across Henry Ford Health's hospital-based community pharmacies in Southeast and Central Michigan.
The partnership will enable 24/7 prescription access for patients and features automated high-capacity storage for safe and accurate prescription retrieval. This innovative system, already widely used in Europe, will allow pharmacy staff to focus on higher-value patient care tasks while improving operational efficiency. The implementation includes capabilities for real-time prescription tracking and can accommodate refrigerated medications, supplies, and over-the-counter products.
BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.
The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.
BD (NYSE: BDX) has launched the Love Your Limbs™ PAD Community Screening Initiative to combat Peripheral Artery Disease (PAD), a circulatory disorder affecting over 21 million Americans and 200 million people globally. The initiative offers free ankle-brachial index screenings in partnership with physicians to detect PAD early.
The company is developing a PAD Health Access Dashboard and Heatmap to identify high-need communities and is partnering with organizations like Ochsner Health and The Way to My Heart. BD is also supporting the American Heart Association's National PAD Action Plan to increase awareness and improve early diagnosis of PAD, which causes over 150,000 preventable amputations annually in the U.S.
BD (NYSE:BDX), a leading global medical technology company, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference. The company's presentation is scheduled for Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time.
Investors and interested parties can access the live webcast of the presentation through BD's investor relations website at investors.bd.com. A replay will be made available on the same platform after the event concludes.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
